These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18031115)

  • 1. Somatomedin-1 (recombinant insulin-like growth factor-1): clinical pharmacology and potential treatment of endocrine and metabolic disorders.
    Laron Z
    BioDrugs; 1999 Jan; 11(1):55-70. PubMed ID: 18031115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of somatomedin-1: yes or no?
    Laron Z
    Paediatr Drugs; 1999; 1(3):155-9. PubMed ID: 10937448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatomedin-1 binding protein-3: insulin-like growth factor-1 binding protein-3, insulin-like growth factor-1 carrier protein.
    BioDrugs; 2003; 17(5):375-9. PubMed ID: 14498768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Insulin-like growth factor 1 (somatomedin C) and its binding proteins 1 and 3 in children with special consideration of diabetes].
    Niedźwiedzka A
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2000; 6(1):51-8. PubMed ID: 12818085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
    Ranke MB
    Trends Endocrinol Metab; 2005; 16(4):190-7. PubMed ID: 15860416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trophic actions of human somatomedin C/insulin-like growth factor I on ovarian cells: in vitro studies with swine granulosa cells.
    Veldhuis JD; Furlanetto RW
    Endocrinology; 1985 Apr; 116(4):1235-42. PubMed ID: 3882403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
    Kemp SF
    BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
    Laron Z
    Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome).
    Savage MO; Blum WF; Ranke MB; Postel-Vinay MC; Cotterill AM; Hall K; Chatelain PG; Preece MA; Rosenfeld RG
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1465-71. PubMed ID: 7505286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A half-century of studies of growth hormone insensitivity/Laron syndrome: A historical perspective.
    Rosenbloom AL
    Growth Horm IGF Res; 2016 Jun; 28():46-50. PubMed ID: 26276451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IGF system in metabolism regulation.
    Binoux M
    Diabete Metab; 1995 Dec; 21(5):330-7. PubMed ID: 8586149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF-1 and insulin as growth hormones.
    Laron Z
    Novartis Found Symp; 2004; 262():56-77; discussion 77-83, 265-8. PubMed ID: 15562823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor -I deficiency.
    Camacho-Hübner C; Savage M
    Horm Res; 2001; 55 Suppl 1():17-20. PubMed ID: 11408756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone and the insulin-like growth factor system in myogenesis.
    Florini JR; Ewton DZ; Coolican SA
    Endocr Rev; 1996 Oct; 17(5):481-517. PubMed ID: 8897022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.